Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://www.ncbi.nlm.nih.gov/pubmed/42785156

Hiroki Shimoda; Junji Yonese; Kosuke Takemura; Masaharu Inoue; Noboru Numao; Ryo Fujiwara; Ryosuke Oki; Takashi Tamiya; Tetsuya Urasaki; Yuji Miura

Sep 25, 2026